Expanded Access Program With Nivolumab to Treat Melanoma
NCT02142218 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2016-09-29
Summary
The purpose of this program is to provide treatment with nivolumab to subjects with Stage III or Stage IV advanced melanoma.
Conditions
- Stage III (Unresectable) or Stage IV Advanced Melanoma
Interventions
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-06-30
- Primary Completion
- 2018-05-31
- Completion
- 2018-05-31
Countries
- United States
- Argentina
- Brazil
- Canada
- Colombia
- Peru
Study Locations
More Related Trials
-
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
NCT04007588 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
NCT01783938 ·Status: COMPLETED ·Phase: PHASE2
-
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
NCT01621490 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection
NCT03980314 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma
NCT02659540 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
NCT02714218 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
NCT03470922 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
NCT03329846 ·Status: COMPLETED ·Phase: PHASE3
-
Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom
NCT03448497 ·Status: COMPLETED
-
The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany
NCT03205722 ·Status: WITHDRAWN
-
A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection
NCT05297565 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
NCT01721746 ·Status: COMPLETED ·Phase: PHASE3
-
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
NCT04674683 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
NCT04099251 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
NCT03724968 ·Status: TERMINATED ·Phase: PHASE2
-
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
NCT02306850 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
NCT02970981 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
NCT02723006 ·Status: TERMINATED ·Phase: PHASE1
-
SBRT as a Vaccination for Metastatic Melanoma
NCT04042506 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma
NCT01709162 ·Status: TERMINATED ·Phase: PHASE2
-
An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself
NCT02320058 ·Status: COMPLETED ·Phase: PHASE2
-
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
NCT02094872 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response
NCT06116461 ·Status: RECRUITING ·Phase: PHASE4
-
Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
NCT03743766 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
NCT04493203 ·Status: COMPLETED ·Phase: PHASE2